Company Filing History:
5 out of 923 
1 out of 245 Years Active: 2010-2021
Title: Innovator Spotlight: Shaopei Cai
Introduction
Shaopei Cai is a notable inventor based in Seattle, WA, with a strong focus in the field of pharmaceutical research and development. He holds six patents that predominantly concern phosphatidylinositol 3-kinase (PI3K) inhibitors. His work aims to provide innovative solutions for various medical conditions mediated by PI3K isoforms.
Latest Patents
Cai's latest patents feature compounds designed as inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K). The compounds detailed in his patent applications include various formulations and encompass pharmaceutically acceptable salts, isomers, and tautomers. The applications recognize the potential of these compounds and pharmaceutical compositions for treating conditions mediated by one or more PI3K isoforms, thus showcasing his contributions to advancements in targeted therapies.
Career Highlights
Throughout his career, Shaopei Cai has contributed to significant organizations including Gilead Sciences, Inc. and Novartis Vaccines & Diagnostics GmbH. His experience within these companies has bolstered his proficiency in pharmaceutical innovation, particularly in the development of inhibitors that can lead to groundbreaking treatments.
Collaborations
Cai has collaborated with esteemed colleagues, including Gary Bruce Phillips and Joshua A Kaplan. Their joint efforts reflect a commitment to advancing research in the pharmaceutical industry and highlight the power of teamwork in driving innovation.
Conclusion
Shaopei Cai exemplifies the spirit of innovation with his dedicated work in developing PI3K inhibitors. His patents not only reflect significant scientific advancements but also illustrate his ongoing commitment to improving healthcare outcomes through targeted pharmaceutical solutions. As an inventor, Cai continues to pave the way for innovative treatments that address critical medical needs.